- AU$125.58m
- AU$113.30m
- AU$27.57m
- 56
- 36
- 40
- 42
Annual balance sheet for Cyclopharm, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 1.87 | 29.2 | 20.3 | 11.7 | 20.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 9.07 | 8.1 | 7.71 | 7.9 | 7.66 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 16 | 43.3 | 36.9 | 30.2 | 42.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.81 | 6.25 | 6.6 | 9.19 | 13.1 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 28.3 | 55.7 | 49.5 | 45.9 | 62.1 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.68 | 7.42 | 7.94 | 8.67 | 10.6 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.2 | 12.7 | 13 | 13.7 | 19.4 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 17.1 | 43.1 | 36.5 | 32.3 | 42.7 |
| Total Liabilities & Shareholders' Equity | 28.3 | 55.7 | 49.5 | 45.9 | 62.1 |
| Total Common Shares Outstanding |